Clearance kinetics of CD34+ cells from peripheral blood: an independent predictor of hematologic recovery after high-dose chemotherapy and hematopoietic stem cell transplantation

[1]  J. Jackson,et al.  Cell adhesion molecule expression on CD34+ cells in grafts and time to myeloid and platelet recovery after autologous stem cell transplantation. , 1998, Experimental hematology.

[2]  Y. Humblet,et al.  Quantification of CD34+ cells mobilized into the peripheral blood predicts the yield of the leukapheresis product and can replace progenitor assays. , 1997, Cytokines, cellular & molecular therapy.

[3]  I McNiece,et al.  Large-scale isolation of CD34+ cells using the Amgen cell selection device results in high levels of purity and recovery. , 1997, Journal of hematotherapy.

[4]  C. Craddock,et al.  Homing and trafficking of hemopoietic progenitor cells. , 1997, Acta haematologica.

[5]  G. Megason,et al.  SPECIFICITY OF HEMATOPOIETIC STEM CELL HOMING , 1996, Hematological oncology.

[6]  J F Keij,et al.  Homing of fluorescently labeled murine hematopoietic stem cells. , 1996, Experimental hematology.

[7]  M. Greaves,et al.  The stem cell antigen CD34 functions as a regulator of hemopoietic cell adhesion. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[9]  L. Schwartzberg,et al.  An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. , 1995, Blood.

[10]  R. Storb,et al.  Factors that influence collection and engraftment of autologous peripheral-blood stem cells. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Seymour,et al.  High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Hardy.  The Homing of Hematopoietic Stem Cells to the Bone Marrow , 1995, The American journal of the medical sciences.

[13]  R. Mick,et al.  Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests. , 1995, Bone marrow transplantation.

[14]  R. Storb,et al.  Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of engraftment after transplantation , 1994, British journal of haematology.

[15]  I. Bernstein,et al.  Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. , 1991, Blood.

[16]  B. Teicher,et al.  A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Canon,et al.  Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts. , 1989, Cancer research.

[18]  S. Aizawa,et al.  Molecular basis of the recognition of intravenously transplanted hemopoietic cells by bone marrow. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[19]  I. Bernstein,et al.  Antigen CD34+ marrow cells engraft lethally irradiated baboons. , 1988, The Journal of clinical investigation.